Stem cell delivery vehicle has potential for future AMD sufferers

Article

Scientists at the University of Southampton have developed biodegradable polymer microspheres which may have the ability to deliver stem cells to damaged retina photoreceptor cells to help with their repair.

Scientists at the University of Southampton have developed biodegradable polymer microspheres which may have the ability to deliver stem cells to damaged retina photoreceptor cells to help with their repair, which offers huge promise for future AMD sufferers.

Andrew Lotery, an eye surgeon and founder of the charity Gift of Sight is working with the researchers to bring the development into clinical applications. According to a report in Chemistry World:, August 2010, the team will be establishing a method to ensure a suspension of microspheres decorated with stem cells, which will be arranged in a particular orientation on the surface could be injected under the retina at the location of the damage. The microspheres would then deliver the stems cells to the damaged photoreceptors and start to repair cells prior to the microspheres biodegrading.

David Chau, told Chemistry World: “Future challenges would include the possibility of incorporating growth factors, drugs or antibiotics into the microspheres that degrade over time to aid repair and regeneration or prevent inflammation following surgery.”

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.